T.E. Witzig

964 total citations
18 papers, 778 citations indexed

About

T.E. Witzig is a scholar working on Hematology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, T.E. Witzig has authored 18 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 7 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in T.E. Witzig's work include Multiple Myeloma Research and Treatments (9 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (3 papers). T.E. Witzig is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer Treatment and Pharmacology (3 papers). T.E. Witzig collaborates with scholars based in United States, Poland and South Africa. T.E. Witzig's co-authors include RA Kyle, Brian Van Ness, Daniel D. Billadeau, TM Therneau, Teresa K. Kimlinger, Daniel J. Sargent, Stephen N. Thibodeau, Kevin C. Halling, M. J. OʼConnell and Daniel J. Schaid and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

T.E. Witzig

17 papers receiving 754 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T.E. Witzig United States 9 416 388 262 200 162 18 778
Christina Kalpadakis Greece 17 235 0.6× 413 1.1× 177 0.7× 156 0.8× 311 1.9× 48 727
PM Kluin Netherlands 9 355 0.9× 539 1.4× 209 0.8× 254 1.3× 372 2.3× 15 973
Pascale De Paepe Belgium 15 387 0.9× 564 1.5× 140 0.5× 268 1.3× 285 1.8× 36 999
A. M. Gianni Italy 15 294 0.7× 201 0.5× 160 0.6× 109 0.5× 83 0.5× 26 619
Jakob Werner Hansen Denmark 13 264 0.6× 414 1.1× 218 0.8× 216 1.1× 260 1.6× 39 822
Carsten Hirt Germany 18 449 1.1× 774 2.0× 120 0.5× 181 0.9× 433 2.7× 42 1.1k
Marie‐Christine Kyrtsonis Greece 18 392 0.9× 421 1.1× 471 1.8× 376 1.9× 497 3.1× 81 1.1k
Julia Steinhilber Germany 15 260 0.6× 392 1.0× 107 0.4× 144 0.7× 235 1.5× 28 652
Rachel L. Sargent United States 15 177 0.4× 434 1.1× 240 0.9× 171 0.9× 471 2.9× 39 851
Marolleau Jp France 7 487 1.2× 654 1.7× 99 0.4× 256 1.3× 290 1.8× 11 919

Countries citing papers authored by T.E. Witzig

Since Specialization
Citations

This map shows the geographic impact of T.E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T.E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T.E. Witzig more than expected).

Fields of papers citing papers by T.E. Witzig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T.E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T.E. Witzig. The network helps show where T.E. Witzig may publish in the future.

Co-authorship network of co-authors of T.E. Witzig

This figure shows the co-authorship network connecting the top 25 collaborators of T.E. Witzig. A scholar is included among the top collaborators of T.E. Witzig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T.E. Witzig. T.E. Witzig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Witzig, T.E., Kami J. Maddocks, Sven de Vos, et al.. (2019). ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. Hematological Oncology. 37(S2). 327–328. 6 indexed citations
2.
Kapoor, Prashant, RA Kyle, S. Vincent Rajkumar, et al.. (2009). A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies. Clinical Lymphoma & Myeloma. 9. S60–S60.
3.
Gertz, MA, MQ Lacy, Angela Dispenzieri, et al.. (2009). A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma. Clinical Lymphoma & Myeloma. 9. S76–S77. 1 indexed citations
4.
Gertz, MA, et al.. (2008). Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica. 93(9). 1402–1406. 11 indexed citations
5.
Kapoor, Prashant, Christine L.H. Snozek, Colin Colby, et al.. (2008). Incorporation of the plasma cell labeling index into the international staging system of multiple myeloma: Impact on prognostic value. Journal of Clinical Oncology. 26(15_suppl). 8591–8591. 2 indexed citations
6.
7.
Witzig, T.E.. (2001). Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma. Blood. 98(2). 7 indexed citations
8.
Galanis, Evanthia, Rimma Goldberg, Pamela J. Atherton, et al.. (2001). Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Annals of Oncology. 12(5). 701–707. 5 indexed citations
9.
Saleh, Mona, Christine A. White, T.E. Witzig, et al.. (2001). Zevalin radioimmunotherapy offers safe and effective therapy for relapsed or refractory, B cell non-Hodgkin's lymphoma (nhl). European Journal of Cancer. 37. S35–S36. 2 indexed citations
10.
Halling, Kevin C., Amy J. French, Shannon K. McDonnell, et al.. (1999). Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers. JNCI Journal of the National Cancer Institute. 91(15). 1295–1303. 307 indexed citations
11.
Rajkumar, S. Vincent, Rafaël Fonseca, MQ Lacy, et al.. (1999). Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplantation. 23(12). 1261–1266. 29 indexed citations
12.
Galanis, Evanthia, Rimma Goldberg, Charles Erlichman, et al.. (1999). Phase I trial of sequential administration of tomudex and 5-iodo-2′-deoxyuridine (IdUrD). European Journal of Cancer. 35. S286–S286. 1 indexed citations
13.
Witzig, T.E., MA Gertz, JA Lust, et al.. (1996). Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. Blood. 88(5). 1780–1787. 86 indexed citations
14.
15.
16.
Billadeau, Daniel D., Patricia T. Greipp, Gregory Ahmann, T.E. Witzig, & Brian Van Ness. (1995). Detection of B-Cells Clonally Related to the Tumor Population in Multiple Myeloma and MGUS. Current topics in microbiology and immunology. 194. 9–16. 8 indexed citations
17.
Clark, Cheryl L., et al.. (1994). Giant uterine fibromyoma producing secondary polycythemia.. PubMed. 84(4 Pt 2). 722–4. 8 indexed citations
18.
O’Neill, Brian Patrick, et al.. (1991). Primary leptomeningeal lymphoma. Neurology. 41(1). 95–95. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina Kalpadakis Breakdown of academic impact, for papers by PM Kluin Breakdown of academic impact, for papers by Pascale De Paepe Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Jakob Werner Hansen Breakdown of academic impact, for papers by Carsten Hirt Breakdown of academic impact, for papers by Marie‐Christine Kyrtsonis Breakdown of academic impact, for papers by Julia Steinhilber Breakdown of academic impact, for papers by Rachel L. Sargent Breakdown of academic impact, for papers by Marolleau Jp
Rankless by CCL
2026